Figure 1:

USP18 null mice exhibit reduced lipolysis. (A) USP18 null mice have higher ratios of fat to body weights as assessed by whole body Magnetic Resonance Imaging (MRI), as compared to wild-type mice. (B) USP18 null mice have decreased in vivo rates of lipolysis. Plasma glycerol and free fatty acid (FFA) levels were measured in these mice before and after injection of the selective β3-adrenergic agonist BRL37344. (C) USP18 null mice had lower adiponectin and higher triglyceride plasma levels. (D) Engineered gain of USP18 expression in human and murine lung cancer cell lines increased acylcarnitine 0:0 levels, as shown in this panel. The symbol * refers to P < 0.05.